Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Rhea-AI Summary

Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, has announced its participation in four major investor conferences in September 2024:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
• 2024 Wells Fargo Healthcare Conference on September 5
• H.C. Wainwright 26th Annual Global Investment Conference on September 11
• 2024 Cantor Fitzgerald Global Healthcare Conference on September 17

The company will participate in fireside chats at each event. Live webcasts of the presentations will be available on Cabaletta Bio's website, with replays accessible for 30 days after each event.

News Market Reaction – CABA

-0.35%

-0.35% Session move

In the trading session that priced this news, CABA declined 0.35%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September:

• Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY.
  
  
• 2024 Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 5, 2024 at 8:00 a.m. ET in Boston, MA.
  
  
• H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Wednesday, September 11, 2024 at 9:00 a.m. ET in New York, NY.
  
  
• 2024 Cantor Fitzgerald Global Healthcare Conference: Fireside chat on Tuesday, September 17, 2024 at 11:30 a.m. ET in New York, NY.
  

A live webcast of each presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Precision AQ
william.gramig@precisionaq.com

FAQ

What investor conferences will Cabaletta Bio (CABA) attend in September 2024?

Cabaletta Bio will participate in four investor conferences in September 2024: Morgan Stanley Global Healthcare Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Fitzgerald Global Healthcare Conference.

When is Cabaletta Bio's (CABA) presentation at the Morgan Stanley Global Healthcare Conference?

Cabaletta Bio will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY.

How can investors access Cabaletta Bio's (CABA) conference presentations?

Investors can access live webcasts of Cabaletta Bio's presentations on the News and Events section of the company's website at www.cabalettabio.com. Replays will be available on the website for 30 days after each event.

What is the focus of Cabaletta Bio's (CABA) research and development?

Cabaletta Bio is focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases.